The CEO of Philip Morris International's U.S. business argued that nicotine is "misunderstood" and contains "cognitive ...

The drug cytisinicline could help expand options for quitting smoking, and if approved by the FDA, would be the first new ...

Smoking status added to the National Cancer Database for patients diagnosed with cancer in 2023 revealed variations in ...

Cytisinicline treatment significantly increased the odds of smoking cessation and reduced nicotine cravings compared with placebo. Cytisinicline significantly increased the likelihood of quitting and ...

Smokers receiving CBT treatment tolerated a smoking cessation intervention well, without interference in the primary treatment goals.

The authors concluded that ORCA-3 reaffirms cytisinicline’s efficacy and tolerability for smoking cessation ... in nicotine cravings and extended cessation benefits through 24 weeks.

The prior ORCA-V1 trial showed efficacy of cytisinicline for vapers looking to quit. For smokers, the ORCA-2 trial showed ...

Paid for by Consumer Action for a Strong Economy. For decades, U.S. tobacco policy has been stagnant. Bureaucracy and ...

ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo Cytisinicline New Drug Application (NDA) Submission ...

Achieve Life Sciences (ACHV) announced that complete trial results from its ORCA-3 were published in the Journal of the American Medical ...

The authors concluded that ORCA-3 reaffirms cytisinicline’s efficacy and tolerability for smoking cessation ... in nicotine cravings and extended cessation benefits through 24 weeks.